Update on new drugs and those in development for the treatment of primary biliary cholangitis

Runalia Bahar, Kimberly A. Wong, Chung H. Liu, Christopher Bowlus

Research output: Contribution to journalArticlepeer-review

17 Scopus citations


Primary biliary cholangitis (PBC) is an autoimmune inflammatory liver disease of the interlobular bile ducts that can lead to cirrhosis and liver failure. Until recently, the only effective treatment was ursodeoxycholic acid (UDCA). However, up to 40% of PBC patients have an inadequate response to UDCA and may continue to have disease progression. Several models have been developed, including the UK-PBC and GLOBE scores, to assist in identifying patients who may benefit from second-line therapies, such as the farnesoid X receptor (FXR) agonist obeticholic acid (OCA). The addition of OCA can significantly improve serum alkaline phosphatase and total bilirubin, which are strong surrogate markers of clinical outcomes in PBC. Other alternatives, including the peroxisome proliferator-activated receptor (PPAR)-? agonists fenofibrate and bezafibrate, may also improve liver biochemistries in PBC patients with an inadequate response to UDCA, but further study is needed to demonstrate their safety and long-term efficacy. Other novel agents, including those targeting the FXR pathway and PPAR-? agonists, have shown promising results and may alter the therapeutic landscape of PBC in the near future. For now, OCA remains the only approved second-line agent for PBC patients with an inadequate response to UDCA while results of long-term studies of its safety and clinical benefit are awaited.

Original languageEnglish (US)
Pages (from-to)154-163
Number of pages10
JournalGastroenterology and Hepatology
Issue number3
StatePublished - Mar 1 2018


  • Farnesoid X receptor
  • FGF19 analog
  • Fibrate
  • Peroxisome proliferator-activated receptor agonist
  • Primary biliary cholangitis
  • Therapy

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology


Dive into the research topics of 'Update on new drugs and those in development for the treatment of primary biliary cholangitis'. Together they form a unique fingerprint.

Cite this